-
The 6th domestically produced PD-1 will be approved soon
Time of Update: 2021-08-27
FinishingrainbowToday, Sina Pharmaceuticals inquired on the official website of the State Food and Drug Administration and found that the recombinant fully human anti-PD-1 monoclonal antibody developed by Yuheng Pharmaceutical/WuXing Biologics-Sepalizumab injection (GLS-010 injection), used For the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma (r/r cHL) above the second-line level, it has entered the “under review” status and is expected to be approved by the NMPA in the near future.
-
More than 1,600 public hospitals in my country's Internet hospitals become the main force for construction
Time of Update: 2021-08-27
According to statistics from the National Health Commission, as of June 2021, there are more than 1,600 Internet hospitals in China, initially forming an online and offline integrated medical service model .
-
"Innovative Drug One Brother" Outbreak This month, 10 Class 1 New Drugs Intensively Strike
Time of Update: 2021-08-27
Sales of terminal anti-tumor drugs in physical pharmacies in cities in China (unit: ten thousand yuan) Source: Mi Nei. com, China's urban physical pharmacy terminal competition pattern For newly approved innovative drugs, retail pharmacies are the main battlefield for sales .
-
Linlu Pharmaceutical Appoints Dr. Feng Luo as Chief Development Officer
Time of Update: 2021-08-27
Feng Luo as the Chief R&D Officer, responsible for the clinical and preclinical/translational medicine department .
In the position of Chief R&D Officer, in addition to leading the establishment of the preclinical and translational medicine department of Linglu, Dr.
-
FDA today accelerates approval of GlaxoSmithKline PD-1 antibody to treat specific solid tumors
Time of Update: 2021-08-27
Today, GlaxoSmithKline (GSK) announced that the US FDA has accelerated the approval of the company’s PD-1 antibody Jemperli (dostarlimab-gxly) for extended indications for the treatment of relapsed or advanced stages with mismatch repair defects (dMMR) Patients with solid tumors .
-
The collection of proprietary Chinese medicines is here!
Time of Update: 2021-08-27
Regarding the centralized procurement catalogue of Hubei Province, the above-mentioned experts told Cyberlan that whether it is chemical drugs, biological preparations or proprietary Chinese medicines, in order to achieve full competition, save medical insurance funds, and reduce the expected effects of patients’ burdens, they all need to be satisfied.
-
The annual treatment cost is less than 20,000 yuan. The fifth domestic PD-1 pricing flows out
Time of Update: 2021-08-27
A few days ago, the fifth domestically produced PD-1-Kangfang Biologics and CP Tianqing's Paimrizumab injection (Annico) is priced out: the retail price is 4875 yuan/100mg, combined with the supportin
-
Focus on monitoring drug sales status and development trends
Time of Update: 2021-08-27
Comparing the key monitoring and rational use catalogs of various provinces shows that all provinces except Inner Mongolia and Tibet have adopted the national version of 20 varieties.
-
Nine Class 1 new drugs were approved clinically from Tengshengbo Pharmaceutical, Hengrui Pharmaceutical, Qilu Pharmaceutical and other companies
Time of Update: 2021-08-27
Text|Pharmaceutical Mission HillsAccording to the latest announcement by the Center for Drug Evaluation (CDE) of the State Drug Administration of China, a number of Class 1 new drugs have recently obtained implied approval for clinical trials, including IL-17A antibody, PD-1/CTLA-4 bispecific antibody, and ERK kinase inhibitor agents of different mechanism of action, of C5a in development of drug targeting antibody, etc.
-
Zhendong Pharmaceutical sells "China's calcium king" and "hair" economy can become a new business growth pole
Time of Update: 2021-08-27
Chart 2: 2017-2021Q1 Langdi calcium carbonate D3 retail market + grade hospitals(Level two and three) Sales scale (unit: million yuan)Data source: Zhongkang CMH, Zhongkang CHIS Kaisi System, Zhongkang Industrial Capital Research CenterThe interim report shows that in the first half of this year, Langdi's calcium series products maintained a steady growth of 48.
-
CSPC Claudin 18.2 targets ADC to initiate clinical co-targeted monoclonal antibody up to US$640 million to go overseas
Time of Update: 2021-08-27
On August 17, the Insight database showed that the SYSA1801 injection, a class 1 new drug of CSPC Jushi Biologics, started clinical trials for CLDN18.
NovaRock will also use its NovaTE bispecific antibody technology platform to collaborate with Flame Biosciences to discover and pre-clinically develop two new double antibodies.
-
The fifth batch of nationally selected drugs started to be listed on the Internet, where should the medical representatives go?
Time of Update: 2021-08-27
AnhuiAnhuiOn July 28, the Anhui Provincial Pharmaceutical Centralized Procurement Service Center issued the "Notice on Declaring the Information of Selected Products Related to the Fifth Batch of National Organizations for Centralized Procurement of Drugs .
-
The State Food and Drug Administration released the 44th batch of generic drug reference preparations catalog
Time of Update: 2021-08-27
Medical Network News on August 19 On August 18, the State Food and Drug Administration issued a notice on the list of generic drugs reference preparations (the 44th batch) .
-
Price reduction of a batch of drugs: up to 90%
Time of Update: 2021-08-27
LiaoningOn August 16, the Centralized Procurement Network of Medicines and Medical Consumables in Liaoning Province issued the "Notice on the Results of the Active Price Reduction of 318 Drugs including Cefadroxil Tablets" .
-
Novartis® (Scucci Yumab) approved for psoriasis in children and adolescents in China
Time of Update: 2021-08-27
In China, Coshanting® has been approved for the treatment of "adult patients with moderate to severe plaque psoriasis who meet the indications of systemic therapy or phototherapy" and "adult patients with ankylosing spondylitis with poor conventional therapy" Patients", and will be officially included in the National Medical Insurance Directory in 2020 .
-
Academician Wu Tianyi: Be the guardian of life on the plateau
Time of Update: 2021-08-26
In order to cope with the high cold and hypoxia and ensure the smooth construction of the railway, Wu Tianyi, as the leader of the expert group, led a team to travel along the Qinghai-Tibet Railway several times to research and determine a complete set of health protection measures and first aid plans .
-
How to protect against the “Delta” epidemic?
Time of Update: 2021-08-26
In the face of mutated strains that spread faster, some experts in the field of disease control suggest gradually improving the mask standards for different application scenarios .
-
Don't let it go!
Time of Update: 2021-08-26
The more people who are vaccinated, the more people who have immunity, forming a protective chain, so that the spread of the new coronavirus in the population can be effectively controlled .
For the new coronavirus vaccine, the duration of immune protection is still collecting data .
-
Xu Jianguo, academician of the Chinese Academy of Engineering: The new coronavirus is natural origin
Time of Update: 2021-08-26
China News Service, Beijing, August 13 (Reporter Huang Yuqin) Xu Jianguo, an academician of the Chinese Academy of Engineering and a medical microbiologist, said at a briefing on the traceability of the new crown virus in China on the 13th that the new crown virus is of natural origin and cannot be manufactured artificially .
-
The combination of "waterlogging" and "epidemic" needs to read the "four-character classic" to improve immunity
Time of Update: 2021-08-26
In the long-term medical practice, Chen Xiaobing put forward the "Four-character Classic of Health", which is actually the "Four-character Classic" for improving immunity, namely, a reasonable diet, moderate exercise, quitting smoking and limiting alcohol, mental balance, adequate sleep, regular physical examination, and control Infection, vaccine priority, beautification of the environment, green water and green mountains .
